Either of these conditions applies:
- The cancer is found in one lymph node region (e.g., neck or underarm) (Stage I).
- The cancer has invaded one extra lymphatic organ or site (denoted by “E”) but not spread to any lymph node regions (Stage IE).
Staging is a careful process that determines whether the cancer cells have moved to other areas of the body and, if so, how extensively. The stage of the disease provides oncologists with insights into its seriousness, which helps them plan the most effective treatments for non-Hodgkin lymphoma.
Staging non-Hodgkin lymphoma may involve one or more of the following tests:
Because lymphoma typically begins in the lymph nodes, the cancer cells can easily spread to various parts of the body, commonly affecting the liver, lungs, bone, and bone marrow.
The current staging system for non-Hodgkin lymphoma (NHL) in adults is known as the Lugano classification, which replaced the older Ann Arbor system. Non-Hodgkin lymphoma is classified into stages I, II, III, or IV, depending on the extent of tumor spread. Limited-stage (I or II) lymphomas that affect an organ outside the lymphatic system (referred to as an extranodal organ) have an E added (e.g., stage IIE).
Unlike other cancers, stage IV lymphomas do not indicate how well or poorly the patient will respond to treatment. Rather, it reflects the specific location of the disease. Even though stage IV NHL is the most advanced, treatment can still be successful.
Either of these conditions applies:
Either of these conditions applies:
Either of these conditions applies:
The lymphoma has spread to at least one organ outside the lymphatic system, such as the bone marrow, liver, or lung.
This term is often used to describe large tumors in the chest and is especially significant for stage II lymphomas, as bulky disease might require more intensive treatment.
Cancer that returns after treatment is called recurrent cancer. It may reappear in the original location or elsewhere in the body. Sometimes, recurrent lymphoma needs to be re-staged using the same system outlined above to determine the best treatment course.
The staging process for non-Hodgkin Lymphoma (NHL) also includes an evaluation of the patient’s prognosis (outcome). The Eastern Cooperative Oncology Group (ECOG) Performance Status is a common scale used to assess a patient's ability to perform daily activities. After the evaluation, the results are graded based on a functional assessment scale.
The (ECOG) Performance Status grades are as follows:
A lower score indicates a better prognosis. Generally, the more independent a person is in walking and performing self-care tasks, the better their prognosis.
Your oncologist will recommend a treatment plan tailored to be most effective based on your NHL stage and overall prognosis. Learn about the treatment options available for non-Hodgkin lymphoma.
At Hematology-Oncology Associates of CNY, we are committed to providing expert, patient-centered care for non-Hodgkin lymphoma. Our team of specialists ensures that each patient receives a personalized treatment plan based on the latest advancements in non-Hodgkin lymphoma.
Our cancer centers provide care for patients in Central New York, in the Syracuse area, including Camillus and all of Onondaga County; Auburn and the rest of Cayuga County; Oneida County, including Utica and Verona; Madison County, including Oneida; Jefferson County, including Watertown; and throughout Oswego County, including Fulton and Oswego.
Source: American Cancer Society, National Cancer Institute.
|
Hematology-Oncology Associates CNY provides cancer treatment, hematology services, access to clinical research trials, therapeutic infusion services, diagnostic imaging, and cancer screening to patients primarily in Central New York, including the Syracuse area, Utica, Oneida, Verona, Watertown, and Oswego, New York. |
